INTRODUCTION: Primary Pulmonary Lymphoepithelioma-like carcinoma (LELC) is a distinct form of Non small cell lung cancer (NSCLC) 3 pathologically similar to undifferentiated nasopharyngeal carcinoma 1. It is associated with Epstein-Barr virus (EBV) 2. In this report we describe a case of a young female who presented with respiratory symptoms and RUL cavitary lesion intially supected for TB later proven to be LELC now undergoing chemo-radiation. CASE PRESENTATION: 32 year-old non-smoker female from Nepal with TB exposure previously was initially treated at Health Department with 10 days of antibiotics for suspected community acquired pneumonia. She had 3 weeks of cough, shortness of breath, pleuritic chest pain, hemoptysis, weight loss and fatigue but denied night sweats or fever and had a negative PPD in 2010. CXR showed a RUL cavitary lesion. When no improvement was seen; IGRA, sputum AFB smears and cultures were taken and she was referred for TB induction therapy in isolation. Later IGRA and sputum AFB x 3 were reported negative. CT chest revealed a cavitary lesion with right mediastinal adenopathy. Patient was placed on airborne isolation and started on RIPE therapy. After 2 weeks patient reported no significant improvement. AFB cultures and Urine histoplasma antigen came out to be negative. Repeat CT chest showed bilateral mediastinal adenopathy with cavitary lesion. Bronchoscopic biopsy revealed malignancy but was indeterminate due to lack of sample size. MRI brain was negative and PET scan showed FDG avidity in right lung lesion and mediastinal nodes. A CT guided core biopsy of the RUL lesion initially indicated a Primary Synovial Sarcoma however FISH for SYT-SXT translocation was negative. EBV testing done was positive and re-review indicated LELC. Chemo-radiation was started with clinical improvement and she remains in treatment.
Background: It is an established fact that beta-blockers (BB) improve survival in patients with HFrEF. However cocaine abusers with HFrEF are currently excluded from this life-saving treatment due to concerns with a theoretical risk of unopposed alpha adrenergic receptor-mediated coronary vasospasms and possible myocardial infarctions (MI). Our study seeks to compare heart failure (HF) outcomes in patients on beta blockers with surreptitious cocaine abuse to those not receiving beta blockers. Methods: From our HF registry, we retrospectively identified 132 patients admitted to the hospital for CHF with related complaints like chest pain or shortness of breath between 2006 and 2008 and cocaine positive drug test. We reviewed the concomitant use of BB in relation to the primary composite end points: MI, total ER visits, HF related admissions 2006-2008, ejection fraction (EF), mean BNP and all- cause mortality. Characteristics of patients with and without BB use were compared using chi-square for categorical and t-test for continuous variables. Considering the variance in baseline characteristics between patients, we also adjusted for co-founding factors like age, sex, Body mass index (BMI) and race before evaluating the independent relationship between BB use and the composite primary endpoints listed above. Results: BB were used in 60 patients (45%), no distinction was made between selective BBs or nonselective BBs. The analysis of our cohort data showed no significant difference in the number of MI (p - 0.819), ER visits (p - 0.627), HF- related admissions (p-0.382), mean BNP (p-0.480), EF (p-0.273) in HF patients using cocaine on BB vs those not on BB. Findings were similar after adjusting for cofounding variables - race, sex, BMI and race (OR for having an MI with BB use was 1.185[95% CI 0.277-5.069]). Conclusions: BB treatment of HFrEF with concomitant cocaine abuse may be safer than previously suggested. Prospectively randomized trials will be needed to clarify the safety of beta blockers in cocaine abusing HFrEF patients. Limitations: Our study was limited by the absence of distinction between selective and nonselective BB as alpha-blocking BBs like carvedilol have been proposed as safe since they can moderate the theoretical alpha mediated effects of cocaine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.